OCT Clinical Unveils OCT Oncology™ Solution Package
OCT Clinical has announced the extension of its services via its OCT Oncology™ solution, to address needs in oncology clinical research, with a special focus on emerging biotechs.
To accomodate the specialized attention emerging oncology therapies often require, OCT Clinical focuses on accelerated access, speedy enrollment, and ultimately cost efficiency.
This is achievied with the help of digital solutions that emerging companies can benefit from:
- CTMS with real-time data access and data hub for risk management
- EDC roll-out tailored to early phase oncology (error-checking during data entry at sites allows for early detection and correction of errors to avoid additional costs associated with the double entry of data from paper-based forms)
- eCRF templates that also help to save time and resources
Read more about the new solution package here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.
